Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


September 02, 2015 12:11 PM ET

Pharmaceuticals

Company Overview of Ocular Therapeutix, Inc.

Company Overview

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies for eye diseases and conditions using its proprietary hydrogel platform technology in the United States. It markets ReSure Sealant, a topical liquid hydrogel that creates a sealant to prevent post-surgical leakage from clear corneal incisions during cataract surgery. The company is involved in developing OTX-DP that is in Phase III clinical trials for post-surgical ocular inflammation and pain; and is in Phase II clinical trials for the treatment of inflammatory dry eye disease, as well as that has completed Phase II clinical trials for the treatment of allergic conjunctivitis...

34 Crosby Drive

Suite 105

Bedford, MA 01730

United States

Founded in 2006

74 Employees

Phone:

781-357-4000

Fax:

781-357-4001

Key Executives for Ocular Therapeutix, Inc.

Founder, Chairman, Chief Executive Officer and President
Age: 48
Total Annual Compensation: $788.8K
Chief Financial Officer and Chief Accounting Officer
Age: 59
Total Annual Compensation: $325.5K
Chief Operating Officer
Age: 56
Total Annual Compensation: $510.3K
Executive Vice President of Clinical, Regulatory and Quality
Age: 58
Total Annual Compensation: $321.5K
Compensation as of Fiscal Year 2014.

Ocular Therapeutix, Inc. Key Developments

Ocular Therapeutix, Inc. Announces Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Ocular Therapeutix, Inc. announced unaudited earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company announced total revenue of $459,000 against $97,000 a year ago. Loss from operations was $9,635,000 against $5,946,000 a year ago. Net loss attributable to common stockholders was $10,009,000 compared to $6,397,000 a year ago. Net loss per share attributable to common stockholders, basic and diluted was $0.45 compared to $2.10 a year ago. For the nine months, the company announced revenue of $885,000 against $124,000 a year ago. Loss from operations was $16,748,000 compared to $12,771,000 a year ago. Net loss attributable to common stockholders was $17,587,000 compared to $13,411,000 a year ago. Net loss per share attributable to common stockholders, basic and diluted was $0.81 against $4.54 a year ago.

Ocular Therapeutix, Inc. to Report Q2, 2015 Results on Aug 10, 2015

Ocular Therapeutix, Inc. announced that they will report Q2, 2015 results at 12:00 PM, GMT Standard Time on Aug 10, 2015

Ocular Therapeutix, Inc., Q2 2015 Earnings Call, Aug 10, 2015

Ocular Therapeutix, Inc., Q2 2015 Earnings Call, Aug 10, 2015

Similar Private Companies By Industry

Company Name Region
Chugai Pharma USA, LLC United States
Ted's Tinctures Inc. United States
Pecos Labs Inc. United States
Aponia Laboratories Inc. United States
Silkit Pharma Corporation United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Ocular Therapeutix, Inc., please visit www.ocutx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.